Miacalcic (Calcitonin Salmon, Synthetic)

Synthetic salmon calcitonin binds to calcitonin receptors located on osteoclast cells. This binding inhibits osteoclast activity, decreasing bone resorption and consequently lowering the release of calcium from bone into the bloodstream. The reduced calcium release also contributes to lower serum calcium concentrations in hypercalcemic states.

The dosage of Miacalcic is determined by the prescribing clinician based on the specific indication, patient characteristics, and route of administration (intramuscular, intravenous, or subcutaneous). Healthcare professionals follow approved labeling and clinical guidelines to select the appropriate amount and frequency for each individual patient.

The safety of synthetic salmon calcitonin during pregnancy and lactation has not been definitively established. Consequently, it should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and necessary import documentation.

Compared with bisphosphonates, calcitonin provides a rapid but generally less potent inhibition of bone resorption and is often used when a short‑term reduction in calcium is needed, such as in hypercalcemia of malignancy. Unlike bisphosphonates, calcitonin is administered by injection and may be preferred in patients who cannot tolerate oral agents, though long‑term efficacy for osteoporosis is lower.

Miacalcic should be stored at 2‑8 °C (refrigerated) in its original packaging. Protect the product from light, do not freeze, and avoid shaking the vial. If temperature excursions occur, discard the product according to local regulations and consult the supplier for replacement.

Miacalcic is supplied as a sterile injection solution and can be given intramuscularly, intravenously, or subcutaneously, depending on the clinical indication and physician preference. Administration is performed by a qualified healthcare professional using aseptic technique, and the injection site should be rotated when multiple doses are required to minimize local reactions.

The most serious adverse reactions to synthetic salmon calcitonin include severe hypersensitivity or anaphylactic responses, profound hypocalcemia that may cause cardiac arrhythmias or seizures, and rare cases of cardiovascular collapse. Patients should be monitored for signs of allergic reaction and for rapid drops in serum calcium, especially during the initial dosing period.

Miacalcic is contraindicated in individuals with known hypersensitivity to salmon calcitonin or any component of the formulation. It should also be avoided in patients with severe renal impairment, uncontrolled hypocalcemia, or those who have experienced severe allergic reactions to previous calcitonin therapy. Clinicians must assess each patient’s medical history before initiating treatment.